A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review

Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with Myelofibrosis.

Data from approximately 1000 participants will be collected. No participants will be enrolled in this study.

Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 156 weeks.

There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 156 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myelofibrosis Bone Marrow Diseases Hematologic Diseases Hemic and Lymphatic Diseases Myeloproliferative Disorders Neoplasms Primary Myelofibrosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Instituto FIDES /ID# 245526, La Plata, Buenos Aires, Argentina

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Treated for myelofibrosis (MF) [primary myelofibrosis (PMF) and secondary myelofibrosis (SMF)].
Must have initiated their first treatment on or after the first date when ruxolitinib was approved in their country of residence and no later than 31 December 2021.

Exclusion criteria

Having received MF treatment in a clinical trial setting.

Treatment and study plan

Primary outcomes

Time from Diagnosis of Myelofibrosis (MF) to Initial Treatment

Time frame: Up to Week 156

Time from diagnosis of MF to initial treatment.
Duration of Initial Treatment

Time frame: Up to Week 156

Duration of initial treatment.
Duration of Second Treatment

Time frame: Up to Week 156

Duration of second treatment.
Duration of Subsequent Treatments

Time frame: Up to Week 156

Duration of subsequent treatments.

Sponsors and collaborators

Lead sponsor

AbbVie

Industry

Registry information

Official study title

A Multi-Country, Real-World Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients Diagnosed With Myelofibrosis Through Chart Review

Acronym: METER

Important dates

Study start: 2022
Primary completion: 2023
Study completion: 2023
First posted: Jul 6, 2022
Registry last updated: Dec 11, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed